ArticleMolecular biology reports2025
RACK1 promotes NF-κB pathway activation and glioma cell proliferation by inhibiting RPS2 ubiquitination.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas are aggressive brain tumors with poor prognosis. Receptor for Activated C Kinase 1 (RACK1) and Ribosomal Protein S2 (RPS2) are linked to tumor progression, but their combined roles in glioblastoma remain unclear.
methodsDifferentially expressed genes (DEGs) from GSE41031 and the Cancer Genome Atlas (TCGA)-glioma datasets were identified and intersected, and protein-protein interaction (PPI) network analysis was performed using multiple algorithms. The expression and function of RACK1 and RPS2 were analyzed in vitro. Co-immunoprecipitation (Co-IP) and ubiquitination experiments analyzed the physical interaction and protein stability of RACK1 and RPS2. NF-κB pathway activity was examined using Western blot and luciferase reporter assays.
resultsBioinformatics analysis revealed that RACK1 and RPS2 were hub genes significantly upregulated in glioma. RACK1 expression was significantly increased in glioma cell lines and promoted cell proliferation, migration and invasion. RACK1 knockdown induced G2/M phase cell arrest by downregulating cyclin B1 and CDK1. Silencing RPS2 also inhibited glioma cell proliferation and colony formation. Mechanistically, RACK1 stabilized RPS2 by inhibiting ubiquitin-mediated RPS2 degradation. RACK1 knockdown accelerated RPS2 degradation and increased its ubiquitination, while MG132 reversed this effect. Both RACK1 and RPS2 positively regulated the NF-κB pathway, and RPS2 overexpression partially rescued the inhibitory effects of RACK1 knockdown on NF-κB pathway and cell growth.
conclusionOur results suggest that RACK1 promotes glioma cell proliferation by promoting NF-κB pathway activation by inhibiting RPS2 ubiquitination, and may serve as a potential biomarker and therapeutic target for glioma progression.
Indexed as
Identifiers
40522528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.